Aurora kinases: novel therapy targets in cancers.
Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. · 2017
Read Aurora kinases: novel therapy targets in cancers. by Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5410356.txt.
Introduction
Anqun Tang and five co-authors review a family of cell-division enzymes as cancer drug targets in a 2017 paper in Oncotarget. The enzymes, called Aurora kinases, steer cell division, above all the fair split of chromosomes into two new cells. They also play a part in egg and sperm formation. When any of them is lost, division fails and embryos suffer, which shows how basic their role is.
Many cancers hold too much of one or more of these enzymes, and that excess helps tumors form and grow. A run of blocker drugs built over past decades slowed many cancers in lab and animal tests. Blocking these enzymes also boosts standard chemotherapy. The review covers each enzyme's build and normal work, its role in cancer, and trial results for blockers paired with standard care.
Catalog record
| CREATOR | Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Aurora kinases: novel therapy targets in cancers By Anqun Tang, Keyu Gao, Laili Chu, Rui Zhang, Jing Yang, Junnian Zheng Published in: Oncotarget DOI: 10.18632/oncotarget.14893 ABSTRACT Abstract Aurora kinases, a family of serine/threonine kinases, consisting of Aurora A (AURKA), Aurora B (AURKB) and Aurora C (AURKC), are essential kinases for cell division via regulating mitosis especially the process of chromosomal segregation. Besides regulating mitosis, Aurora kinases have been implicated in regulating meiosis. The deletion of Aurora kinases could lead to failure of cell division and impair the embryonic development. Overexpression or gene amplification of Aurora kinases has been clarified in a number of cancers. And a growing number of studies have demonstrated that inhibition of Aurora kinases could potentiate the effect of chemotherapies. For the past decades, a series of Aurora kinases inhibitors (AKIs) developed effectively repress the progression and growth of many cancers both in vivo and in vitro, suggesting that Aurora kinases could be a novel therapeutic target. In this review, we'll first briefly present the structure, localization and physiological functions of Aurora kinases in mitosis, then describe the oncogenic role of Aurora kinases in tumorigenesis, we shall finally discuss the outcomes of AKIs combination with conventional therapy. Keywords: Aurora kinases, mitosis, cancer therapy target, Aurora kinases inhibitors, combination therapy INTRODUCTION Mitosis controlling the mother cells to divide into two daughter cells with equal chromosomes and cytoplasm is accurately regulated by a series of serine/threonine kinases in cell cycle, and among which Aurora kinases are important and indispensable in multiple steps of mitotic progression. The three members of Aurora kinases family [1] hold high homogeneity in mammalian cells. In term of the role of mitotic regulators, deletion of AURKA caused mitotic spindle assembly and chromosome segregation failure, subsequently resulted in genetic instability and a significantly increased tumor incidence [2–4]. In addition, Aurora kinases deficiency also caused polyploid oocytes in mice [5], and early embryonic lethality has been observed in AURKA−/− mice [2, 6]. Loss of AURKB activity could override spindle assembly checkpoint (SAC) through premature removal of SAC proteins from the kinetochore [7], which leads to defect of chromosome segregation and conformation of polyploidy. Overexpression or amplification of Aurora kinases is generally detected in amount of human cancers, such as breast cancer [8–11], ovarian cancer [12–14], gastric/gastrointestinal cancer [15, 16] and other tumors [11, 17–33] (Table 1) and is associated with the poor prognosis [8, 34, 35]. Thus, Aurora kinases become promising therapeutic targets and numerous AKIs have been developed. In present review, we outline the recent progresses along with the emerging obstacles associated with Aurora kinases in cancers. [Table: Summary of Aurora kinases and Aurora kinases inhibitors in clinical trails] STRUCTURE, LOCALIZATION AND FUNCTIONS OF AURORA KINASES IN MITOSIS Structure of Aurora kinases Aurora kinases are highly conserved and hold homologous structure, constituting of a N-terminal domain, a protein kinase domain and C-terminal domain [36–39]. High consistency among Aurora kinases is found in the catalytic domain of the C-terminal containing catalytic T-loop and degradation box (A-box/D-box/KEN-box). Under physical mitosis, Aurora kinases can be targeted and activated by several protein cofactors including target protein for Xenopus kinesin-like protein 2 (TPX2) and inner centromere protein (INCENP). Additionally, each kinase of Aurora family members is activated through auto-phosphorylation on catalytic T-loop residues which are Thr288 (AURKA), Thr232 (AURKB) and Thr195 (AURKC), respectively (Figure 1A). Upon dephosphorylation mediated by protein phosphatase 1(PP1), the activities of Aurora kinases become inactive [40]. In the late mitosis, Aurora kinases are recognized by anaphase-promoting complex/cyclosome (APC/C) and subsequently degraded. [Figure: Structure and cellular distribution of Aurora kinases in mitosisA. Schematic drawing of AURKA, AURKB and AURKC proteins with indicated domains. B. Cellular localization shift of Aurora kinases in mitosis (AURKC is not shown due to the elusive cellular localization and function).] Localization of Aurora kinases AURKA localizes to the duplicate centrosomes from the beginning of S phase and shifts to the bipolar spindle microtubules during mitosis, finally, moves to perinuclear materials of the daughter cell at the end of mitosis [41]. By contrast, AURKB starts at early G2 and localizes to the chromosomes in prophase, the centromere in prometaphase and metaphase, the central spindle in anaphase and the mid-body in cytokinesis [42]. Recent study identified that AURKC localized to centrosome in the interphase and binded to chromosome during mitosis [43]. However, the exact distribution shift of AURKC during the mitosis is still non-established (Figure 1B). Based on their distinct subcellular localizations during mitosis (Table 1), the functions of Aurora kinases are distinguished and summarized in Table 1. Functions of Aurora kinases Once localizing to centrosome, AURKA is activated by LIM protein ajuba, and the expression and activity of AURKA arrives peak at G2/M transition, stimulating duplicated centrosomes to separate at G2/M transition and initiating the mitotic entry. Activated AURKA recruits several pericentriolar proteins including γ-tubulin and TACC/MAP215 [44, 45] to microtubule organizing center (MTOCs) which facilitates centrosome maturation and speedy microtubule nucleation in eukaryotic cell. After nuclear membrane breaks down in prometaphase, AURKA is activated, targeted to microtubule by TPX2 [46, 47], and required for spindle assembly and the conformation of bipolar spindle microtubule [48]. At the end of the mitosis, AURKA is degraded by cadherin-1(Cdh1)/APC/C complex [49], and mitotic exist. AURKB is a component of chromosome passenger complex (CPC), composing of additional three activation regulators INCEP, survivin and borealin [50–53]. It mediates chromosome condensation by phosphorylating histone H3 on Ser10 and variant centrosome protein A (CENP-A) on Ser7 [54]. AURKB is also involved in regulating SAC, rectifying the faulty attachment between spindle and kinetochore, maintaining the correct chromosome alignment and the faithful chromosomal segregation. Most recent study demonstrated that activated AURKB mediated phosphorylation of Histone H2AX at Ser121, which in turn promoted the auto-phosphorylation of AURKB, forming a positive feedback and further accelerating AURKB activation [55]. During anaphase, AURKB phosphorylates a series of downstream substrates, including mitotic kinesin-like protein 1 (MKLP1) and RacGAP1 [56], facilitates their deposition at mid-body, and maintains the stabilization of central spindle. Moreover, AURKB could phosphorylate Kif2A, the microtubule de-polymerase, leading to shorten of central spindle, and promote cytokinesis [57]. Unlike AURKA and AURKB, AURKC is specifically expressed in mammalian testis compared to other somatic tissues [58]. Forced-expression of mutant AURKC in mouse oocytes causes oocytes cell cycle arrest at meiosis I and formulating eggs of aneuploidy, implicating that AURKC exerts pivotal role in meiotic chromosome segregation [59]. Since AURKC is required as part of the CPC [60, 61], AURKC has overlapping functions with AURKB in mitosis [62, 63]. Recent study demonstrated that AURKC interacted with transforming acidic coiled-coil 1 (TACC 1) and co-localized to the mid-body of Hela cells during cytokinesis [64]. THE ROLES OF AURORA KINASES IN CANCER AURKA, B and C are mapped on intrinsic unstable with frequent defection, amplification and mutations regions of 20q13.2, 17p13.1 and 10q13, respectively [65–67], giving a good explanation of abnormal expression of Aurora kinases in human cancers. So far, no reports have shown that natural deficiency of Aurora kinases in human tumors. However, amount of studies have demonstrated that the overexpression or amplification of Aurora kinases has been observed in various human cancers as showed in Table 1, and several types of Aurora kinases mutations have been detected in different somatic